ntah, kawan ku bukan group ini, tapi selalu dapat news dari kawan2 - remiser, dealers, dia rajin baca, but tak selalu ikut recommendations buy, kadang2 je ikut
U read la... 2019 profit only 6mill of 53mill revenue. There is only one exec director.. his salary u know how much? 4 million that year. U want to invest ka with company like this. He doesnt care one.. just wallop 300k a month even 2018 the company was at loss
Jordan_Tulid U read la... 2019 profit only 6mill of 53mill revenue. There is only one exec director.. his salary u know how much? 4 million that year. U want to invest ka with company like this. He doesnt care one.. just wallop 300k a month even 2018 the company was at loss 11/12/2019 11:58 PM
Regulatory Body Approves Marketing of SELENA That Can Detect 3 Eye Diseases 01.10.2019
Oct 2019 – It is with great pleasure to announce EyRIS’s first medical device after Heath Science Authority of Singapore (HSA) gave us the official approval. Our patented medical device, SELENA , is an effective assistive tool in the diagnosis of 3 eye diseases, diabetic retinopathy (DR), Glaucoma and Age-Related Macular Degeneration (AMD).
Health Science Authority This approval closely follows the ISO13485:2016 certification we received for our Quality Management System (QMS) where we had to demonstrate our ability to provide medical devices and related services that consistently meet customer and HSA regulatory requirements.
There are more than 415 million diabetics in the world today who require an annual eye check-up to prevent vision loss. Statistically, 3 in 10 diabetics suffer from diabetes induced eye disease and 1 in 10 develops blindness when left untreated.
In South-East Asia alone, there are near 100 million persons who suffer from diabetes, more than 10% of the population. A World Health Organization report in 2017 highlighted a recent dramatic increase in diabetes and critically, “half of those cases remain undiagnosed, underscoring the need for rapid, low-cost solutions to reach the region’s underserved areas”.
With the approval, we aim to assist stakeholders develop their screening programs
pada ku kaunter ini ok je, something got to do with health, good for long term, aging population pun makin meningkat, so ada keperluan....issue tak buat profit adalah perkara biasa dalam product softwares, sebab nak buat sebijik pun telan banyak belanja, so nak cepat untung, kena market, market and market the products sampai jadi macam revenue, kalau tak sanggup tunggu boleh je lari kikiki
Xkenal pon. Pada ku you stay or you leave personal choice. Nobody paksa you. Kalau ku unhappy, ku cari tempat lain yang boleh buat ku happy. Hari2 cakap unhappy pun tak jadi apa pon
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
Twowah123
654 posts
Posted by Twowah123 > 2019-12-04 09:19 | Report Abuse
If cn hold long long time go ahead with novamsc.